Analysts at Brean Capital initiated coverage on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a report released on Tuesday. The brokerage set a “buy” rating and a $221.00 price target on the biopharmaceutical company’s stock. Brean Capital’s price target would suggest a potential upside of 80.94% from the company’s current price.

A number of other analysts also recently commented on the company. Piper Jaffray Cos. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, June 26th. Credit Suisse Group AG raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Leerink Swann reissued a “buy” rating and issued a $200.00 target price on shares of Alexion Pharmaceuticals in a report on Sunday, July 17th. Robert W. Baird reissued a “neutral” rating and issued a $145.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, June 13th. Finally, SunTrust Banks Inc. dropped their target price on Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a report on Wednesday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $178.32.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 122.14 on Tuesday. Alexion Pharmaceuticals has a 12-month low of $110.56 and a 12-month high of $193.45. The stock has a market capitalization of $27.39 billion, a P/E ratio of 306.88 and a beta of 1.33. The firm’s 50-day moving average price is $128.84 and its 200 day moving average price is $135.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The business’s revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.44 EPS. Analysts predict that Alexion Pharmaceuticals will post $4.67 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, CEO David Hallal sold 332 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the transaction, the chief executive officer now owns 189,266 shares of the company’s stock, valued at $25,955,939.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Heidi L. Wagner sold 222 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $30,445.08. Following the transaction, the senior vice president now directly owns 32,115 shares in the company, valued at approximately $4,404,251.10. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can purchased a new stake in shares of Alexion Pharmaceuticals during the second quarter worth about $34,314,000. Legal & General Group Plc boosted its stake in Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock valued at $128,153,000 after buying an additional 35,267 shares during the last quarter. Strs Ohio boosted its stake in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock valued at $65,398,000 after buying an additional 52,710 shares during the last quarter. Gateway Investment Advisers LLC boosted its stake in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock valued at $21,582,000 after buying an additional 23,032 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in Alexion Pharmaceuticals by 4.4% in the second quarter. Candriam Luxembourg S.C.A. now owns 143,411 shares of the biopharmaceutical company’s stock valued at $16,745,000 after buying an additional 6,017 shares during the last quarter. 96.34% of the stock is currently owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.